The acquisition targets share two traits: steep selling prices and a focus on protein-based drugs, called biologics.

FORBES: Magazine Article

RichardClarkRichard Clark, Merck's chief executive, says, "We believe we can be the leaders" in the follow-on biologics field based on the GlycoFi technology.

FORBES

Richard Clark , Merck's chief executive, says, "We believe we can be the leaders" in the follow-on biologics field based on the GlycoFi technology.

FORBES: Big Pharma